NovaBridge BiosciencesNBP
Recorded

NovaBridge Biosciences Jefferies Global Healthcare Conference

Review the key takeaways and the transcript of this earnings call.

Period 0Duration18 minParticipants3

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

The 2026 Jefferies Healthcare Conference. It's my pleasure to introduce Srishti Gupta, CEO of NovaBridge Biosciences, and Jeff Nau, CEO of Visara. As a reminder, this will be a 20-minute presentation followed by five minutes of Q&A. Srishti, Jeff, over to you.

Srishti GuptaCEO

Thank you. Morning, everybody. Thank you for joining us. As we just said, Jeff is the CEO of Visara, which is a majority-owned subsidiary of NovaBridge. It's an ophthalmology-focused company. We'll talk a little bit about NovaBridge's portfolio today, and then we'll go into the Visara portfolio as well. Oh, the slides are not formatted well. It's okay. These are the forward-looking statements. Oh, wait. Sorry. Can we Sorry. NovaBridge is a clinical-stage biotech company, and we're building, creating value around differentiated assets in oncology and in ophthalmology. There we go. In oncology, we have a lead program called givastomig. I'll spend some time on that today. Ophthalmology is the basis of our Visara company that we created around it, and Jeff will be going into the portfolio and the forward plans for that company.

Srishti GuptaCEO

Underlying all of this is the fact that we're an integrated U.S.-China company. Half our team sits in China, half our team sits in the U.S., and we're integrated across clinical development and business development. A lot of what we're doing in terms of portfolio creation is looking for differentiated assets in the China ecosystem. givastomig is a Claudin 18.2 4-1BB bispecific that's being worked up for frontline gastric cancer. It is the lead program in our oncology portfolio, and we have worked this program from phase I about 18 months ago to being phase III ready right now. At ESMO recently, we presented our data for the phase I study, which now includes 71 patients, and I'll go through some of that data today. For us, givastomig represents the ability to have a very strong global clinical development team.

Srishti GuptaCEO

Stretching across China and the U.S., our team has been able to advance this program to phase III ready with registration plans in the U.S., in Europe, and in Japan. Visara is a purpose-built subsidiary company that we have that started with an anchor asset in Claudin 18.2, and then acquired other assets along the way, which Jeff will walk through. Here's a quick view of our portfolio in oncology. In addition to givastomig, we have two other programs, ragistomig and uliledlimab. For us, this represents the ability to work closely with partners, where partners are advancing the programs, and then we're able to look at the data and advance only when we think the program warrants the next step. It's very efficient capital deployment.

Srishti GuptaCEO

Ragi, we are working on with ABL Bio, which is a Korean biotech, and uliledlimab is a program that is with our partner in China, TJ Bio, and they have out-licensed the development of that to Sanofi. Jeff will walk through these portfolios on the ophthalmology side. Givastomig, as I mentioned, is a Claudin 18.2 4-1BB conditional activation, and what differentiates this asset is really two things. One is the fact that the 4-1BB is only activated in the tumor microenvironment when the Claudin 18.2 binds to its binding site. For us, this allows for the ability to avoid some of the systemic side effects that are normally seen with 4-1BB. The anti-immune activity is only within the tumor microenvironment. The second thing that is really interesting about our Claudin 18.2 is that it has an Fc region with a high-affinity binding.

Srishti GuptaCEO

In the biology, when we looked at this program, we thought that this would have the ability to be active across a broad range of Claudin expression levels. This was the biology in which we went into our clinical development program. As you can see here in the waterfall plot, we actually do have a broad range of activity across Claudin, high and low, and we defined high and low based on the commercial cutoff set by zolbetuximab with 74% as the cutoff in terms of percentage of cells that express Claudin. As you can see, we have both low Claudin patients as well as high Claudin patients, and that is true for both the eight and the 12 doses, which were eight and 12 milligram doses, which were run in the phase I-B study.

Srishti GuptaCEO

More than just the overall, the response rate that we saw in anti-tumor activity, I think what is really impressive is that we see a median PFS of 16.9 months, and that is in the group that we have the longest follow-up for, which is 17.8 months overall. The other group, the 12 milligram is currently at 10.4 months, but that is an evolving median PFS, so many of those results are still censored, and as the time for follow-up increases, we are seeing that converge to where the eight milligrams is. Also very interesting is that we have the 77% six-month median PFS, and at 12 months, it is 60%, and the median duration of response is 15.2 months. When we were looking at givastomig and thinking about how it could be differentiated in frontline gastric cancer, we really looked at four things. The first was broad eligibility, broad patient eligibility.

Srishti GuptaCEO

As you see, we have both the Claudin-low and the Claudin-high patients. This actually doubles the number of patients that were eligible today for Claudin-based therapies. The second thing for us was that it was deep and durable responses. Our landmark PFS for the eight milligram dose is around 77% and about 60% for the 12 month. Any grade treatment-related adverse events is the third piece of this. We really want to ensure that givastomig has a high tolerability for patients. As you can see, we have only a 23% grade 3 or higher adverse event rate for the eight milligrams. It is a bit higher for the 12 milligrams. Finally, practical administration. As we were thinking about this is something that can be added to the backbone. It does not require titration. It does not require any active monitoring during the infusion.

Srishti GuptaCEO

It is added on to the standard of care, which is nivolumab and FOLFOX. Givastomig is a validated target, so we are trying to ensure that in our phase III study, we can validate it in the same patient population where zolbetuximab is active today. Because of its binding affinity, we are going to be expanding that patient eligibility to the entire range of Claudin patients. Over time, we would like to also expand this within gastric cancer, so we are looking at CPS or PD-L1 low patients, HER2-positive patients, and perioperative disease. Then finally, as we think about other solid tumors in the gastrointestinal tract, we are thinking about BTC, PDAC, which are already enrolling in the phase I studies, as well as other studies that might be in addition on different immuno-oncology backbones.

Srishti GuptaCEO

With that, I will hand it over to Jeff, and he will talk to you a little bit about the Visara programs.

Jeff NauCEO

Thanks, Srishti. Good morning. What I will talk about today with Visara is we have three clinical assets in the pipeline, and this curated pipeline has really been pulled together to look at both front and back of the eye. You will see on the left-hand side, our first asset, VIS-102, is a modified recombinant human nerve growth factor asset. This product is modified in such a way that it allows for 24 months of refrigerated storage, so we can allow patients to receive nerve growth factor not as a frozen product, as is currently delivered, but as a refrigerated product that is ready to use in a blow-fill-seal packaging, which is pretty consistent with what we would deliver for rewetting drops or dry eye products.

Jeff NauCEO

The second asset is for a disease that has no current treatment that is approved by the FDA, which is ocular surface squamous neoplasia, which is basically squamous cell carcinoma of the conjunctiva and cornea. This is a peptibody platform, and what you will see here is on an Ig chimera backbone, two interferon alpha mimetics, which act as interferon, and I will talk a little bit about why interferon is important in a moment. Then the third asset on our peptibody platform is a tetravalent VEGF-Ang2 peptibody. This is a product that is built on an IgG backbone with two Ang2 peptides that are high affinity for Ang2.

Jeff NauCEO

From the standpoint of how this product fits into the marketplace, this is a large-format product, so fairly similar in molecular weight to Vabysmo, but it has two anti-VEGF-A binding sites and two ANG-2 binding sites, so much higher avidity than what we would see in the rest of the marketplace. We now have two small studies that have shown that patients can go after loading as long as six months. 50% of patients will go as long as six months without another injection. When we look at the market opportunities here, the first asset is in a market that is $2 billion-$3 billion globally, about $1.2 billion in the U.S. The only competitor product is Oxervate. If we look at the second asset, there is no competition. We estimate this to be about a half a billion to a billion-dollar marketplace.

Jeff NauCEO

The third one, most of us know how big the anti-VEGF market is at $8 billion. From the standpoint of this pipeline, we are really excited because we do think this is high probability of success with these MOA. There are no unknown MOAs here. We have high confidence to take all three of these products to BLA, and really, the question is, how much of the market do we take from this pipeline? When we talk about VIS-102, which is the modified recombinant human nerve growth factor asset, you will see for neurotrophic keratitis on the left-hand side, you can see these patients present with a persistent epithelial defect, which means the epithelium covering of the cornea is missing. Often comes from herpetic disease, but can come from things like acidic or basic damage of the cornea. It could come from nerve damage of the underlying trigeminal nerve.

Jeff NauCEO

What you are seeing there on the left is before treatment with our product, and on the right, after treatment. So you can see the clear cornea on both the bottom pictures. Again, Oxervate is the only FDA-approved product on the market at the moment. What we intend to bring to the table for this marketplace is a product that is going to be very well accepted by physicians and patients. You can see that the current product has to be stored at minus 20 through the entire specialty pharma supply chain. The patient needs to then keep it in a freezer at their home, and then they have to give the product to themselves six times a day. So they have to take the product out, thaw it, draw it up into a syringe, administer it to their eye. For patients that have poor dexterity, this is a problem.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day